TPEX:3118

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Level Biotechnology

Market Cap

NT$1.0b

Last Updated

2021/06/18 08:35 UTC

Data Sources

Company Financials

Executive Summary

Level Biotechnology Inc. markets and distributes cell culture, immunology, and molecular biology products in Taiwan. More Details


Snowflake Analysis

Flawless balance sheet and good value.

Share Price & News

How has Level Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 3118 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 3118's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-0.8%

3118

-0.1%

TW Healthcare

1.3%

TW Market


1 Year Return

-17.3%

3118

11.8%

TW Healthcare

48.5%

TW Market

Return vs Industry: 3118 underperformed the TW Healthcare industry which returned 11.9% over the past year.

Return vs Market: 3118 underperformed the TW Market which returned 48.1% over the past year.


Shareholder returns

3118IndustryMarket
7 Day-0.8%-0.1%1.3%
30 Day-2.3%3.1%8.1%
90 Day3.8%1.1%8.0%
1 Year-17.3%-17.3%15.3%11.8%53.3%48.5%
3 Year8.9%-4.7%46.9%32.6%75.9%55.7%
5 Year15.7%-10.2%78.5%48.6%140.8%97.9%

Long-Term Price Volatility Vs. Market

How volatile is Level Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Level Biotechnology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 3118 (NT$31.35) is trading below our estimate of fair value (NT$108.72)

Significantly Below Fair Value: 3118 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 3118 is good value based on its PE Ratio (14.8x) compared to the TW Healthcare industry average (16.8x).

PE vs Market: 3118 is good value based on its PE Ratio (14.8x) compared to the TW market (17.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 3118's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 3118's PB Ratio (1.8x) is in line with the TW Healthcare industry average.


Future Growth

How is Level Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Level Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Level Biotechnology performed over the past 5 years?

-7.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3118 has high quality earnings.

Growing Profit Margin: 3118's current net profit margins (9.8%) are higher than last year (7.5%).


Past Earnings Growth Analysis

Earnings Trend: 3118's earnings have declined by 7.7% per year over the past 5 years.

Accelerating Growth: 3118's earnings growth over the past year (44.5%) exceeds its 5-year average (-7.7% per year).

Earnings vs Industry: 3118 earnings growth over the past year (44.5%) exceeded the Healthcare industry -2.6%.


Return on Equity

High ROE: 3118's Return on Equity (12.5%) is considered low.


Financial Health

How is Level Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: 3118's short term assets (NT$604.5M) exceed its short term liabilities (NT$197.4M).

Long Term Liabilities: 3118's short term assets (NT$604.5M) exceed its long term liabilities (NT$18.3M).


Debt to Equity History and Analysis

Debt Level: 3118 is debt free.

Reducing Debt: 3118 has not had any debt for past 5 years.

Debt Coverage: 3118 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 3118 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Level Biotechnology current dividend yield, its reliability and sustainability?

3.19%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 3118's dividend (3.19%) is higher than the bottom 25% of dividend payers in the TW market (2.04%).

High Dividend: 3118's dividend (3.19%) is low compared to the top 25% of dividend payers in the TW market (5.01%).


Stability and Growth of Payments

Stable Dividend: 3118 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 3118 has only been paying a dividend for 8 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (61.3%), 3118's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Level Biotechnology has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Level Biotechnology Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Level Biotechnology Inc.
  • Ticker: 3118
  • Exchange: TPEX
  • Founded: 1989
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: NT$1.017b
  • Shares outstanding: 32.45m
  • Website: https://www.level.com.tw

Number of Employees


Location

  • Level Biotechnology Inc.
  • No. 80, Kangning Street
  • Lane 169
  • New Taipei City
  • 221
  • Taiwan

Listings


Biography

Level Biotechnology Inc. markets and distributes cell culture, immunology, and molecular biology products in Taiwan. The company also engages in marketing and distribution of biomedical precision equipment...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/18 08:35
End of Day Share Price2021/06/17 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.